Data demonstrate potential superiority of antibody-based T cell engager CDR404 over TCR-based approaches, consistent with emerging Phase 1 trial signals of ...

CatalYm today announced the presentation of the first preclinical data demonstrating that the company's clinical-stage antibody visugromab can improve the anti-tumor activity of antibody-drug ...

Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster presentation ...

Alector has completed subject enrolment in the Phase II trial of AL101/GSK4527226 in individuals with early Alzheimer's ...

Single and multi-dose studies of the small molecule TREM2 agonist VG-3927 clear early safety hurdle. Meanwhile, new findings ...

It binds both transmembrane and soluble TREM2, triggering a rise in CSF sTREM2. Single and multi-dose studies of the small ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild ...

Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

Data Standards Body website - Contains additional information on the CDR and the DSB as well as notifications of the latest developments. Data Standards - The published contents of the standards in ...

The proposed CDR-scanning method starts with known CDR sequences from an already characterized antibody and generates and tests actual antibodies, each having a mutation at one of the CDR residues ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of 113 health care workers in Catalonia who were followed for three years.